Singer D, La E, Graham J, Grace M, Poston S, Molnar D. Cost-effectiveness of adjuvanted RSVPreF3 vaccination in adults aged 50-59 years with cardiopulmonary diseases in the United States. Poster presented at the ISPOR 2024; May 8, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S137. doi: 10.1016/j.jval.2024.03.735
Singer D, La E, Graham J, Grace M, Poston S, Molnar D. Cost effectiveness of adjuvanted RSVPreF3 vaccination in adults aged 50-59 years with diabetes in the United States. Poster presented at the American Diabetes Association's 84th Scientific Sessions; June 21, 2024. Orlando, FL. [abstract] Diabetes. 2024 Jun; 73(Suppl 1):1045.
Molnar D, La E, Verelst F, Curran D, Poston S, Van Bellinghen LA, Graham J. Assessing the public health impact of the adjuvanted respiratory syncytial virus prefusion F protein vaccine among older adults in the United States (US). Poster presented at the ISPOR 2023 Conference; May 8, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S172. doi: 10.1016/j.jval.2023.03.927
Graham J, Kassouf W, Tomaras D, Kurt M, Patel M, Teitsson S. Cost-utility of nivolumab versus observation for the adjuvant treatment of urothelial carcinoma (UC) for patients who are at high-risk of recurrence: a Canada public payer perspective. Poster presented at the ISPOR 2023 Conference; May 8, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S66-7. doi: 10.1016/j.jval.2023.03.347
Verelst F, La E, Graham J, Molnar D. Leveraging time-use data to estimate market and non-market productivity losses due to respiratory syncytial virus (RSV) disease among adults aged ≥60 years in the United States (US). Poster presented at the ISPOR 2023 Conference; May 9, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S120. doi: 10.1016/j.jval.2023.03.632
Talbird S, Graham J, Anderson S, Nossov M, Beattie N, Lains Sousa C, Rak A, Masters III H, Diaz-Mitoma F. Health and economic impact of a novel 3-antigen vaccine for the prevention of hepatitis B in adults in Germany: a cost-effectiveness analysis. Poster presented at the ISPOR Europe 2022; November 8, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S135. doi: 10.1016/j.jval.2022.09.649
Zinan Y, Graham J, Diaz-Decaro J, Myers E, Lumley M, Buck P. The public health impact of routine vaccination in 16- to 40-year-old females for the prevention of cytomegalovirus and congenital cytomegalovirus in the United Kingdom. Poster presented at the ISPOR Europe 2022; November 7, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S200-1. doi: 10.1016/j.jval.2022.09.972
Yi Z, Graham J, Diaz-Decaro J, Myers E, Buck P. The public health impact of routine vaccination in 16-40-year-old females for the prevention of cytomegalovirus and congenital cytomegalovirus in the United States. Poster presented at the ISPOR 2022 Conference; May 15, 2022. Washington, DC. [abstract] Value Health. 2022 Jun; 25(6 S1).
Filonenko A, Purser M, Mader G, Graham J. Impact of increased utilization of long-acting reversable contraceptive methods among young women on cost and unintended pregnancies (UP) in the United States (US). Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S153. doi: 10.1016/j.jval.2020.04.371
Yi Z, Mauskopf J, Herring W, Graham J. Challenges in estimating eligible population size in budget-impact analyses for new health care technologies. Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S288. doi: 10.1016/j.jval.2020.04.371
Schelfhout J, Jiang Y, Miles L, Merchant S, Graham J. Cost effectiveness of letermovir as cytomegalovirus prophylaxis in in allogeneic hematopoietic stem cell transplant recipients. Poster presented at the 2018 BMT Tandem Meetings; February 2018. Salt Lake City, UT. [abstract] Biol Blood Marrow Transplant. 2018 Mar; 24(3 Supplement):S384. doi: 10.1016/j.bbmt.2017.12.473
Johnson KD, Jiang Y, Weiss T, Graham J. Herpes zoster vaccine effectiveness and waning of effectiveness. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 24, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A326.
Graham J, Johnson K, Jiang Y, Weiss T. Comparing the estimated potential health impact of 2 herpes zoster vaccines in the United States. Poster presented at the 2017 AMCP Managed Care & Specialty Pharmacy Annual Meeting; March 27, 2017. Denver, CO. [abstract] J Manag Care Spec Pharm. 2017 Mar; 23(3a):S3.
Graham J, Xuan D, Luthra R, Borker R, Earnshaw SE, Lim J. Budget impact analysis of afatinib for the first-line treatment of metastatic non-small cell lung cancer patients with epidermal growth factor receptor exon 19 deletion mutations in a U.S. health plan. Poster presented at the 2016 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 2016. San Francisco, CA. [abstract] J Manag Care Pharm. 2016 Apr; 22(4-a):S30.
Mladsi DM, Graham JB, Ronquest NA. Trade-off analysis: an extension of threshold pricing analysis. Poster presented at the 2012 ISPOR 17th Annual International Meeting; June 7, 2012. Washington, DC. [abstract] Value Health. 2012 Jun; 15(4):A169.
Lynen R, Taylor TN, Farkouh RA, Candrilli SD, Graham J, Colligs A. The effect of age, race, and folic acid-containing supplements on red blood cell folate levels among United States women of child bearing age. Poster presented at the ASRM Annual Meeting; October 26, 2010. [abstract] Fertil Steril. 2010 Sep; 94(4, Suppl 1):S93. doi: 10.1016/j.fertnstert.2010.07.392
Lynen R, Farkouh RA, Taylor TN, Graham J, Colligs A, Lindemann M. Potential impact of using folate-fortified oral contraceptives on risk of neural tube defects in the United States. Poster presented at the 2010 ASRM Annual Meeting; October 2010. [abstract] Fertil Steril. 2010 Sep; 94((4) Suppl 1):S5.
Talbird SE, Bell K, Graham JB, Deal L, Mauskopf J. Cost-effectiveness analysis for treatment of symptomatic uterine fibroids among premenopausal women seeking to retain uterus. Poster presented at the 2010 ISPOR 15th Annual International Meeting; May 26, 2010. [abstract] Value Health. 2010 May; 13(3):A183.
Mauskopf J, Graham JB, Bae J, Gaich C. Impact of including prasugrel on the formulary for patients who undergo percutaneous coronary intervention for acute coronary syndrome. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 28, 2009. [abstract] Value Health. 2009 Oct; 12(7):A322.
Graham JB, Earnshaw SR, Castelli-Haley J, Oleen-Burkey M, Johnson KP. Cost-effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis in the presence of long-term clinical evidence. Poster presented at the 2007 ISPOR 10th Annual European Congress; October 24, 2007. [abstract] Value Health. 2007 Nov; 10(6):A381.